PassFinals
Musculoskeletal

Sjogren syndrome

Sjogren disease is a chronic autoimmune condition causing ocular, oral and other mucosal dryness, with possible joint, skin, lung, renal, neurological and haematological involvement; persistent gland swelling or systemic features need specialist assessment because lymphoma risk is increased.

In a nutshell

Sjogren disease causes persistent ocular and oral dryness but can affect lungs, kidneys, nerves, joints, skin and blood. Confirm the pattern with objective eye and salivary testing, serology and specialist assessment; anti-Ro supports but does not prove the diagnosis. Protect eyes and teeth, replace or stimulate secretions, assess systemic disease, and urgently investigate persistent firm or asymmetric gland swelling, nodes or B symptoms for lymphoma.

Classic presentation

A person with gritty dry eyes, a dry mouth needing frequent drinks, dental caries or candidiasis, fatigue and arthralgia, with or without parotid swelling and positive anti-Ro/SSA.

Key points

  • Dry eyes and dry mouth have many causes; medication review and objective testing are essential.
  • Anti-Ro/SSA supports Sjogren disease but is not completely specific and a negative result does not exclude it.
  • Schirmer or ocular-surface testing and salivary flow or gland assessment support the diagnosis; labial biopsy is useful when uncertainty remains.
  • Protect the ocular surface and teeth first; use specialist ophthalmic treatment for severe or inflammatory dry eye.
  • Do not use systemic immunosuppression for uncomplicated dryness; treat significant extraglandular disease through rheumatology and organ specialists.
  • Persistent firm, asymmetric or enlarging gland swelling, nodes, purpura, B symptoms or splenomegaly need urgent lymphoma assessment.
  • Anti-Ro or anti-La positivity matters in pregnancy: plan early with rheumatology, obstetrics and fetal cardiology.

First-line investigation

History and examination with medicine review, autoimmune and safety blood tests, objective ocular and salivary testing, and targeted systemic assessment.

Management

Confirm the sicca pattern and assess systemic disease

  • Exclude common drug and non-autoimmune causes, perform objective ocular and salivary assessment, obtain appropriate serology and assess for connective-tissue disease and organ involvement.1,2

Protect eyes, mouth and teeth

  • Use regular ocular lubricants, water or saliva substitutes, sugar-free stimulation, fluoride dental care and prompt treatment of candidiasis; refer severe eye disease to ophthalmology.1,5,2

Stimulate secretions and manage fatigue or pain

  • Consider specialist or BNF-guided pilocarpine when residual gland function and safety criteria permit; use activity, sleep, psychological and symptom strategies for fatigue and pain.1,7

Treat systemic complications through specialists

  • Refer urgently for lung, renal, neurological, vasculitic, haematological or other organ-threatening disease; use conventional immunosuppression or biologics only for selected systemic complications under specialist care.1,6,7

Monitor lymphoma risk, pregnancy and treatment safety

  • Safety-net for persistent gland swelling, nodes, B symptoms, vision change, breathlessness, neurological or renal symptoms, and plan anti-Ro or anti-La positive pregnancy with specialist obstetric care.1,2

Exam traps

  • A positive ANA or anti-Ro without compatible symptoms does not diagnose Sjogren disease.
  • A negative anti-Ro does not exclude disease; consider specialist assessment and labial biopsy when appropriate.
  • Schirmer testing alone is not the diagnosis and does not assess systemic disease.
  • Do not treat uncomplicated sicca with systemic immunosuppression or routine biologics.
  • Persistent hard or asymmetric parotid swelling is not just a flare; investigate for lymphoma.
  • Anti-Ro or anti-La positive pregnancy needs coordinated fetal cardiac planning, not reassurance alone.

Illustrations

Illustration of Schirmer testA clinical photograph or clean diagram of a Schirmer test, with a filter-paper strip at the lower eyelid margin and a five-minute tear-wetting measurement. Add a note that it is one part of objective ocular assessment, not a stand-alone diagnosis.User:Milorad Dimic MD, Wikimedia Commons · CC-BY-SA-3.0
Focal lymphocytic sialadenitis in Sjogren diseaseH&E micrograph of a minor salivary-gland lip biopsy showing focal lymphocytic infiltration around ducts and acini. Label the specimen as supportive diagnostic evidence and avoid implying that every patient requires biopsy.KGH, Wikimedia Commons · CC-BY-SA-3.0

Key sources

  1. British Society for Rheumatology guideline on management of adult and juvenile onset Sjogren disease (Current UK specialist guideline covering diagnosis, objective glandular testing, systemic assessment, sicca treatment, systemic disease, lymphoma risk, pregnancy and follow-up; Rheumatology 2025;64:409-439)Published 1 Feb 2025
  2. NHS, Sjogren syndrome (NHS condition information on symptoms, alternative causes, diagnosis, symptomatic treatment, dental and eye care, lymphoma warning symptoms and pregnancy; last reviewed 27 November 2024)Updated 27 Nov 2024
  3. NHS Greater Glasgow and Clyde, Suspected connective tissue disease (UK NHS primary-care referral resource describing sicca, salivary-gland swelling and antibody interpretation; last reviewed 21 September 2025)Updated 21 Sept 2025
  4. British Society for Rheumatology guideline scope for Sjogren syndrome (UK guideline scope describing suspected-disease serology, ocular testing, salivary testing and minor-gland biopsy in the diagnostic pathway)
  5. NICE TA369, Ciclosporin for treating dry eye disease that has not improved despite artificial tears (NICE technology appraisal for specialist ciclosporin treatment in adults with appropriate severe dry-eye disease; published 16 December 2015 and last reviewed 31 December 2018)Published 16 Dec 2015 | Updated 31 Dec 2018
  6. NHS England, Rituximab for primary Sjogren syndrome in adults (Current NHS England specialised commissioning policy: rituximab is not routinely commissioned for primary Sjogren syndrome except under the policy criteria; first published 22 August 2016 and page updated 20 April 2026)Published 22 Aug 2016 | Updated 20 Apr 2026
  7. BNF, current prescribing information for pilocarpine, hydroxychloroquine and topical treatments (Current UK prescribing source for indications, contraindications, interactions, dosing, monitoring and adverse effects; direct access was restricted and the browser session was unavailable, so unsupported doses were omitted)
  8. British Society for Rheumatology Sjogren disease guideline executive summary (Open executive summary of the current BSR guideline, including pilocarpine, pregnancy, biologic and follow-up recommendations)

This page is exam revision material, not medical advice, and must not be used for patient care. Always check drug doses against the BNF and current guidance. Full disclaimer.